Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group.

Shim HS, Chung JH, Kim L, Chang S, Kim WS, Lee GK, Jung SH, Jang SJ.

Korean J Pathol. 2013 Apr;47(2):100-6. doi: 10.4132/KoreanJPathol.2013.47.2.100. Epub 2013 Apr 24.

3.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12. Review.

4.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
5.

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G.

J Clin Oncol. 2011 May 20;29(15):2121-7. doi: 10.1200/JCO.2010.31.8923. Epub 2011 Apr 11.

PMID:
21482992
6.

Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).

Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S.

Anticancer Res. 2015 Jul;35(7):3885-91.

PMID:
26124334
7.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
9.
10.
11.

Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.

Chen YM.

J Chin Med Assoc. 2013 May;76(5):249-57. doi: 10.1016/j.jcma.2013.01.010. Epub 2013 Mar 22. Review.

12.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.

Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Review.

PMID:
27223332
13.

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M.

Arch Pathol Lab Med. 2013 Jun;137(6):828-60. doi: 10.5858/arpa.2012-0720-OA. Epub 2013 Apr 3. Erratum in: Arch Pathol Lab Med. 2013 Sep;137(9):1174.

14.
15.

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M.

J Thorac Oncol. 2013 Jul;8(7):823-59. doi: 10.1097/JTO.0b013e318290868f. Erratum in: J Thorac Oncol. 2013 Oct;8(10):1343.

16.

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.

Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI.

Ann Oncol. 2013 Aug;24(8):2080-7. doi: 10.1093/annonc/mdt127. Epub 2013 Apr 4.

PMID:
23559152
17.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.

Cho SH, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.

Cancer Chemother Pharmacol. 2012 Aug;70(2):315-20. doi: 10.1007/s00280-012-1876-0. Epub 2012 Jul 4.

PMID:
22760226
18.

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB.

J Thorac Oncol. 2010 Jul;5(7):1048-53. doi: 10.1097/JTO.0b013e3181dd1386.

19.

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Riely GJ.

J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S146-9. doi: 10.1097/JTO.0b013e318174e96e. Review.

20.

Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.

Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ.

Lung Cancer. 2015 Mar;87(3):311-7. doi: 10.1016/j.lungcan.2015.01.004. Epub 2015 Jan 14.

PMID:
25617986

Supplemental Content

Support Center